跳到正文
原文
Endpoints News 生物医药· Anna Brown·· 10 天前AI 评分35

Neurosterix 筹集 1.05 亿美元用于精神分裂症药物开发

Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets

AI 导读

Neurosterix 获得 1.05 亿美元 B 轮融资,旨在推进其用于治疗精神分裂症的候选药物。公司重组了 Cobenfy 的核心团队。

正文

Neu­roster­ix, which is re­unit­ing some key fig­ures be­hind Coben­fy, has cor­ralled $105 mil­lion in a Se­ries B to fund its lead schiz­o­phre­nia can­di­date that hits …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news